REFERENCES


22. Early Breast Cancer Trialists'


57. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast...


151. Robertson JF. Fulvestrant (Faslodex®)—How to Make a Good Drug Better. 2007; 12: 774-84.


166. Leeming DJ, Koizumi M, Qvist P, et al. Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers. Biomark Cancer 2011; 3: 15-23.


expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. *Gynecol Oncol* 2012; **124**: 142-7.


198. Tan DS, Rothermundt C, Thomas K, et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and


